Laryngeal Cryotherapy for Neurogenic Cough: Safety, Feasibility, and Prospective Outcomes
The Laryngoscope · 09.07.2026
DOI: 10.1002/lary.70723 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, online erschienen am 09.07.2026. Verfasst von Shumon I Dhar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Laryngology, Department of Otolaryngology-Head and Neck Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Broncho-Esophagological Association (ABEA) Young Investigator Research Grant.
Abstract (Originalsprache)
Objectives
Despite the prevalence of neurogenic chronic cough (NCC), treatment options remain limited. This study investigates selective laryngeal cryotherapy (SLC) as a potential sensory neurolytic therapy. The primary objective was to explore the feasibility and safety of SLC, while the secondary objectives assessed efficacy in the reduction of laryngeal hypersensation and cough symptoms.
Methods
Patients with refractory NCC were prospectively recruited. Patients underwent laryngeal laser sensory testing (LST), immediately followed by awake SLC treatment. Cough measures including the cough severity index (CSI) and urge to cough visual analog scale (UTC‐VAS) were collected at baseline and regular intervals. At 1‐month postprocedure, additional LST was performed. Safety, tolerability, and adverse events were recorded.
Results
Thirty patients with NCC were enrolled. All patients successfully completed awake SLC. There were no serious adverse events or unanticipated adverse device effects. 21% of patients experienced at least one treatment‐emergent adverse event, all of which self‐resolved within 2 days. Post‐SLC patients had a higher mean laser power threshold, 7.5 W (SD 2.42) to trigger a cough response compared to their baseline threshold of 2.8 W (SD 2.76) ( p < 0.001). By 6 months, patients demonstrated sustained improvement compared to their baseline, with a reduction in CSI of −8.25 (95% CI 11.60, −4.91) ( p < 0.001) and UTC‐VAS −18.07 (95% CI −29.71, −6.43) ( p = 0.003).
Conclusions
The data suggest that awake laryngeal cryotherapy is feasible, tolerable, and safe. SLC reduced laryngeal hypersensitivity, and while it is a promising treatment option for neurogenic cough, further research is required to confirm its long‐term effectiveness. Level of Evidence 4.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Laryngology, Department of Otolaryngology-Head and Neck Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- O'Donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Division of Laryngology, Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
- Department of Speech, Language and Hearing, School of Behavioral and Brain Sciences, University of Texas at Dallas, Richardson, Texas, USA.
- Division of Laryngology, Department of Otolaryngology-Head & Neck Surgery, Stanford University School of Medicine, Stanford, California, USA.
ORCID-Profile: Shumon I Dhar, Alexandra D D'Oto, Adrianna Shembel, Ted Mau
Förderung
- American Broncho-Esophagological Association (ABEA) Young Investigator Research Grant
Zitieren
APA
Dhar, S. I., Allen, E., Liu, Y. L., D'Oto, A. D., Suresh, R., Shembel, A., & Mau, T. (2026). Laryngeal Cryotherapy for Neurogenic Cough: Safety, Feasibility, and Prospective Outcomes. The Laryngoscope. https://doi.org/10.1002/lary.70723
Vancouver
Dhar SI, Allen E, Liu YL, D'Oto AD, Suresh R, Shembel A, et al. Laryngeal Cryotherapy for Neurogenic Cough: Safety, Feasibility, and Prospective Outcomes. The Laryngoscope. 2026. doi:10.1002/lary.70723
BibTeX
@article{Dhar2026,
author = {Dhar, Shumon I and Allen, Eric and Liu, Yun-Lun and D'Oto, Alexandra D and Suresh, Rishi and Shembel, Adrianna and Mau, Ted},
title = {Laryngeal Cryotherapy for Neurogenic Cough: Safety, Feasibility, and Prospective Outcomes},
journal = {The Laryngoscope},
year = {2026},
doi = {10.1002/lary.70723}
}
EUVIMED